The effect of nitro-oleic versus losartan in diabetic nephropathy: modulation of parathyroid hormone related protein

Mohammed, Asmaa; Sadek, Nermeen Bakr; Eshra, Mohamed A.; Khowailed, Effat A.; Rashed, Laila Ahmed; Aboulhoda, Basma Emad

doi:10.5603/fm.a2018.0057

Cited by 2 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 studies [ 6 , 7 , 10 , 12 , 16 , 20 – 22 , 24 , 26 , 31 ] analyzed urinary albumin. Meta-analysis results showed that MD = −52.68, 95% CI (-77.78, -27.59), P < 0.0001, and I 2 = 97%.…”

Section: Resultsmentioning

confidence: 99%

Efficacy and Safety of Jinshuibao Capsule in Diabetic Nephropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Yu¹,

Yan

Lan³

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Objective. This systematic review was able to evaluate the clinical evidence of JSBC in the randomized controlled trial (RCT) of diabetic nephropathy. Methods. The Chinese and English literatures published in PubMed, Cochrane Library, VIP, Wanfang Data, CNKI, and CBM before July 30, 2019, were retrieved. This study includes only randomized controlled trials of treatments related to diabetic nephropathy. We assessed the methodological quality of the subjects involved according to the assessment criteria in 5.3.3 of the Cochrane Assessment Manual. RevMan 3.5.5 software was used to analyze the relevant data, meta-analysis, and inverted funnel analysis chart. Results. This study included 26 RCTs, including 4676 patients in total (2342 cases in the experimental group and 2334 cases in the control group). The results of 8 randomized controlled trials showed that urinary microprotein excretion rate (UAER) significantly decreased ( P < 0.0001 ) before and after treatment of diabetic nephropathy. Conclusion. The available clinical evidence has suggested that JSBC combined with western drugs is differentially effective in the treatment of diabetic nephropathy. The combination of JSBC with western medicine is more effective. However, due to the small amount and low quality of the included literatures, the current evidence is not certain to be fully clinically applicable.

show abstract

Section: Resultsmentioning

confidence: 99%

Efficacy and Safety of Jinshuibao Capsule in Diabetic Nephropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Yu¹,

Yan

Lan³

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…Another study has shown that administration of losartan to DN model rat resulted in improvements in systolic blood pressure, serum glucose, urea, GFR, and a decrease in serum Ang-II levels. Histopathological results showed clear improvement in glomerulosclerosis, vascular and tubular injury parameters in the losartan group (28).…”

Section: Discussionmentioning

confidence: 86%

Comparative effects of candesartan and losartan on mesangial expansion and glomerular volume in diabetes rat model receiving rosmarinic acid therapy

Samsu,

Sakti,

Rifai

2024

J Nephropathol

View full text Add to dashboard Cite

Introduction: An oxidative stress and angiotensin II (Ang II) contribute significantly in the pathogenesis of diabetic nephropathy (DN). Therefore, interventions targeting these factors are anticipated to significantly contribute to inhibiting the progression of diabetic kidney disease. Objectives: The aim of this study was to assess the impact of a combination of rosmarinic acid (RA) and angiotensin receptor blockers (ARBs) in preventing mesangial expansion and reducing glomerular volume in streptozotocin (STZ)-induced diabetic rats. Materials and Methods: We observed experimental animals, 16 adults male Wistar rats, which were randomly grouped into 4 groups (n=4 per group): negative and positive control groups and diabetic rats treated with RA 75 mg/kg and candesartan 1 mg/kg (treatment group 1) and RA therapy 75 mg/kg and losartan 2.5 mg/kg (treatment group 2). Following 8 weeks of therapy, the renal histology was assessed to evaluate mesangial expansion and glomerular volume. Results: In comparison to the positive control, treatment group 1 demonstrated a significant inhibition of mesangial expansion (MD: -19.92; 95% CI: -21.97, -17.87; P<0.001) and decreased glomerular volume (MD: 2669.06; 95% CI: 2066.31, 3271.80; P<0.001). Similarly, treatment group 2 significantly inhibited mesangial expansion (MD: -19.21; 95% CI: -21.26, -17.16; P<0.001) and decreased glomerular volume (MD: 2488.04; 95% CI: 1885.29, 3090.78; P<0.001) compared to the positive control. While treatment group 1 exhibited better effects than treatment group 2, although the difference was not statistically significant. Conclusion: In STZ-induced diabetic rats, combination therapy of RA with candesartan or losartan can inhibit mesangial expansion and decrease glomerular volume.

show abstract

The effect of nitro-oleic versus losartan in diabetic nephropathy: modulation of parathyroid hormone related protein

Abstract: Both pre and post-DN losartan, NO2-OA may have a potential role in protection and regression of DN through reduction of PTHrP overexpression.

Cited by 2 publications

References 26 publications

Efficacy and Safety of Jinshuibao Capsule in Diabetic Nephropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Efficacy and Safety of Jinshuibao Capsule in Diabetic Nephropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Comparative effects of candesartan and losartan on mesangial expansion and glomerular volume in diabetes rat model receiving rosmarinic acid therapy

Contact Info

Product

Resources

About